Headquartered in Monheim (Germany), Cube is a leading provider of both products and services that allow for samples of purified, highly stable membrane proteins to be obtained. These play a key role as receptors for new drugs but they are extremely difficult to extract without loss of native functionality.

Founded in 2012, Cube is now recognized as a highly reputable and recognized player in its sector and serves a diversified client base, comprising some of the top 10 Big Pharma companies. Cube has also strengthened its position in North America with the opening in 2013 of a subsidiary in Wayne (United States).

  • Investment date

    2021

  • Sector

    Life Sciences

  • Transaction type

    Buy-Out

  • Growth theme

    Product innovation / International expansion

  • Location

    Germany